SCHEMBL5755255

SCHEMBL5755255

NCc1ccc(S(=O)(=O)c2ncc[nH]2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 4/20 0.46
CA2 P00918 4/20 0.46
CA9 Q16790 3/20 0.46
CA12 O43570 2/20 0.46
CA4 P22748 2/20 0.46
CA6 P23280 1/20 0.46
CA5A P35218 1/20 0.46
CA7 P43166 1/20 0.46
CA14 Q9ULX7 1/20 0.46
CA5B Q9Y2D0 1/20 0.46
MAPT P10636 1/20 0.44
PSIP1 O75475 1/20 0.43
TXNRD1 Q16881 1/20 0.39
KDM4E B2RXH2 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
HTR6 P50406 1/20 0.37
ADRB2 P07550 1/20 0.36
MMP2 P08253 5/20 0.35
MMP9 P14780 5/20 0.35
MMP8 P22894 5/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28102125 0.81 TSHR (0.52) CA1CA2CA9CA12CA4
SCHEMBL1097174 0.78 GAA (0.52) CA1CA2CA9CA12CA6
SCHEMBL4728735 0.78 HTR6 (0.48) TXNRD1KDM4ESMN1; SMN2HTR6
SCHEMBL5759642 0.75 LOXL2 (0.58) CA1CA2CA9CA12CA4
SCHEMBL4730459 0.75 TXNRD1 (0.39) CA1CA2TXNRD1
SCHEMBL28102213 0.74 KMT2A (0.51) CA1CA2CA9CA12CA4
SCHEMBL6680428 0.74 CA1 (0.70) CA1CA2CA9CA12CA4
SCHEMBL502541 0.74 TXNRD1 (0.44) CA1CA2TXNRD1KDM4ESMN1; SMN2
SCHEMBL27342398 0.73 MGMT (0.39) CA1CA2CA9HTR6LOXL2
SCHEMBL5755064 0.73 CA1 (0.52) CA1CA2CA9CA12CA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1562902-B1 2-PYRIDONE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE ASTRAZENECA AB (SE) 2006-05-03 EP disclosed
US-20060035938-A1 2-Pyridone derivatives as inhibitors of neutrophile elastase ASRAZENECA AB (SE) 2006-02-16 US disclosed
EP-1562902-A1 2-PYRIDONE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE AstraZeneca AB (SE) 2005-08-17 EP disclosed
WO-2004043924-A1 2-PYRIDONE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE ASTRAZENECA AB (SE) 2004-05-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060035938-A1 2-Pyridone derivatives as inhibitors of neutrophile elastase SERPINB1, ELANE, SERPINE1 CA1 4595/4885CA2 2787/4885CA9 4393/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.